(Q36947038)

17 August 2017

1 reference

title

EGFR, HER2 and VEGF pathways: validated targets for cancer treatment (English)

1 reference

17 August 2017

2

Heinz-Josef Lenz

1 reference

17 August 2017

Michael F Press

1

1 reference

17 August 2017

1 January 2007

1 reference

17 August 2017

1 reference

17 August 2017

67

1 reference

17 August 2017

2045-2075

1 reference

17 August 2017

14

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767140-00006

17 August 2017

0 references

cites work

Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767140-00006

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767140-00006

Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767140-00006

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

12 December 2020

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

1 reference

12 December 2020

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

12 December 2020

Vascular endothelial growth factor as a target for anticancer therapy

1 reference

12 December 2020

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

12 December 2020

The role of overexpressed HER2 in transformation

1 reference

12 December 2020

Immunolocalization of Epidermal Growth Factor Receptors in Normal Developing Human Skin

1 reference

12 December 2020

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

12 December 2020

Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial

1 reference

12 December 2020

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

12 December 2020

The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia

1 reference

12 December 2020

Targeted cancer therapy

1 reference

12 December 2020

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories

1 reference

12 December 2020

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

12 December 2020

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

1 reference

12 December 2020

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

12 December 2020

Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).

1 reference

12 December 2020

Novel approaches for targeted cancer therapy

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

12 December 2020

High interstitial fluid pressure - an obstacle in cancer therapy

1 reference

12 December 2020

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

12 December 2020

The continuum of care: a paradigm for the management of metastatic colorectal cancer

1 reference

12 December 2020

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

1 reference

12 December 2020

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

12 December 2020

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

12 December 2020

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

12 December 2020

Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival

1 reference

12 December 2020

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

12 December 2020

Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor

1 reference

12 December 2020

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

1 reference

12 December 2020

Vascular endothelial growth factor receptors: expression and function in solid tumors

1 reference

12 December 2020

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

12 December 2020

Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.

1 reference

12 December 2020

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

12 December 2020

Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib

1 reference

12 December 2020

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

1 reference

12 December 2020

Herstatin, an autoinhibitor of the human epidermal growth factor receptor 2 tyrosine kinase, modulates epidermal growth factor signaling pathways resulting in growth arrest

1 reference

12 December 2020

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

12 December 2020

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

12 December 2020

SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.

1 reference

12 December 2020

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

12 December 2020

Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases

1 reference

12 December 2020

Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.

1 reference

12 December 2020

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

1 reference

12 December 2020

The basic biology of HER2.

1 reference

12 December 2020

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients

1 reference

12 December 2020

Cetuximab therapy and symptomatic hypomagnesemia

1 reference

12 December 2020

Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines

1 reference

12 December 2020

Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.

1 reference

12 December 2020

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

1 reference

12 December 2020

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

12 December 2020

Antiangiogenic cancer therapy

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model

1 reference

12 December 2020

Clinical studies with non-iressa EGFR tyrosine kinase inhibitors

1 reference

12 December 2020

Untangling the ErbB signalling network

1 reference

12 December 2020

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

1 reference

12 December 2020

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

12 December 2020

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

12 December 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

12 December 2020

Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts

1 reference

12 December 2020

Rash correlates with tumour response after cetuximab

1 reference

12 December 2020

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

1 reference

12 December 2020

ADAM proteases, ErbB pathways and cancer

1 reference

12 December 2020

Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab

1 reference

12 December 2020

Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3

1 reference

12 December 2020

A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.

1 reference

12 December 2020

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

12 December 2020

The discovery of receptor tyrosine kinases: targets for cancer therapy

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model

1 reference

12 December 2020

Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.

1 reference

12 December 2020

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

12 December 2020

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

12 December 2020

Why the epidermal growth factor receptor? The rationale for cancer therapy

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer

1 reference

12 December 2020

Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer

1 reference

12 December 2020

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

1 reference

12 December 2020

Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors

1 reference

12 December 2020

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

1 reference

12 December 2020

Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells

1 reference

12 December 2020

Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis

1 reference

12 December 2020

1 reference

12 December 2020

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

1 reference

12 December 2020

Association with membrane protrusions makes ErbB2 an internalization-resistant receptor

1 reference

12 December 2020

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

1 reference

12 December 2020

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

12 December 2020

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

12 December 2020

Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions.

1 reference

12 December 2020

Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.

1 reference

12 December 2020

Vaccination against the HER-2/neu oncogenic protein

1 reference

12 December 2020

Lung cancer: intragenic ERBB2 kinase mutations in tumours

1 reference

12 December 2020

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

12 December 2020

Tyrosine phosphorylation mapping of the epidermal growth factor receptor signaling pathway

1 reference

12 December 2020

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

1 reference

12 December 2020

A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer

1 reference

12 December 2020

Resistance to anti-VEGF agents

1 reference

12 December 2020

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

12 December 2020

Breast cancer--loss of PTEN predicts resistance to treatment

1 reference

12 December 2020

Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer

1 reference

12 December 2020

Preclinical data targeting vascular endothelial growth factor in colorectal cancer

1 reference

12 December 2020

10.2165/00003495-200767140-00006

Identifiers

DOI

1 reference

PubMed ID

17883287

Dimensions Publication ID

17 August 2017

0 references

1 reference

PubMed ID

17883287